RUNX2 and gastric cancer: We performed a subgroup analysis of the two genes in the same datasets; to our surprise, we found that among the patients with diffuse and poorly differentiated GC, those with higher expression of RUNX2 had a significantly higher median survival time than those with lower RUNX2 expression, whereas patients with lower expression of FN1 had a significantly longer median survival time than those with higher FN1 expression (Figure 4c and d).